Huons Global Establishes Botulinum Toxin Specialist 'Huons Biopharma'

Physical Spin-off of Botulinum Toxin Business

Kim Young-mok, CEO of Huons Biopharma (Photo by Huons Group)

[Asia Economy Reporter Kim Ji-hee] Huons Global, the holding company of Huons Group, announced on the 1st that it has spun off its bio business division to establish an independent corporation, Huons Biopharma. This spin-off was carried out to strengthen the expertise in the bio business, which is considered a future growth engine including botulinum toxin, and to reorganize the business structure to maximize future competitiveness.

Huons Biopharma will be responsible for clinical development of botulinum toxin and bio new drug development projects, including ▲supporting the global expansion of 'Hutox' ▲expanding indications for 'Liztox' ▲conducting domestic clinical trials of botulinum toxin ‘HU-045’ with reduced resistance development. At the same time, it plans to focus on developing bio new drugs in the aesthetic field. After stabilizing the business, an IPO will also be pursued.

Kim Young-mok, Executive Director, was appointed as the head of Huons Biopharma. Born in 1969, CEO Kim earned a Ph.D. in Biochemistry from Kyung Hee University. He joined Huons Group after working at pharmaceutical and bio companies such as Dongkook Pharmaceutical, ATGen (currently NK Max), and Anguk Pharmaceutical. At Huons Global, he served as head of the bio division and developed Liztox (export name Hutox).

CEO Kim stated, “Huons Biopharma plans to create opportunities in the global market rather than being limited to the domestic market,” adding, “This year, we will officially start clinical trials in China and advance into global markets such as Europe, making this the inaugural year for Huons Group’s botulinum toxin business to grow to the next level.”

This content was produced with the assistance of AI translation services.